Authors
Latest:
Expert highlights cybersecurity regulation updates for health care organizationsThere have been several recent regulatory updates related to cybersecurity in health care.
Latest:
iRARC adoption is slow but persistent in bladder cancer"Over the past 10 to 15 years, tremendous efforts have gone into robotic surgical innovation to improve perioperative morbidity for patients with bladder cancer undergoing RC," write Andrew M. Wood, MD, and Nima Almassi, MD.
Latest:
Going “retro”: A perspective on robotic retroperitoneal renal surgeryImprovements in technology have renewed interest in the technique.
Latest:
Strategies to mitigate impact of intravenous ICM shortage"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.
Latest:
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Latest:
Advantages and limitations of AI in prostate cancerInterest in AI in prostate cancer pathology has picked up speed since initial attempts of computer-aided diagnosis of the disease more than a decade ago, according to Peter A. Humphrey, MD, PhD.
Latest:
Future Directions in Prostate Cancer TreatmentDrs Smith and Helfand look ahead and provide their thoughts on future directions in the treatment of patients with prostate cancer.
Latest:
Asked by a Resident: Dr. Efe Chantal Ghanney Simons interviews Dr. Mark S. Litwin"The most important thing I feel I've learned in my life so far is the value of human interaction and human connection," says Mark S. Litwin, MD, MPH.
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
Ryan Hankins, MD, on rectal spacer utilization and erectile dysfunctionData showed a link between counties with higher rectal spacer use and a lower prevalence of ED at 4 to 5 years.
Latest:
Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate CancerJack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic castration-resistant prostate cancer (nmCRPC) show darolutamide may offer superior tolerability with lower discontinuation rates and fewer drug interactions, while emphasizing the importance of critically evaluating real-world studies by examining methodology rather than just conclusions.
Latest:
5 ways health care practices can mitigate cyberattack riskIn the world of health care, factors such as remote care, complex IT environments, and connected health care devices are creating new avenues for cybercriminals to target.
Latest:
Urologic implications of Lynch syndromeResearch indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.
Latest:
Urologist discusses drug cost savings, price transparency“I think the great thing about Cost Plus Drugs is that, as we mentioned, it's simple, but it's also price transparent," says Raymond Xu, MD.
Latest:
What is genetic discrimination, and why does it matter?Fear of discrimination has downstream effects on health care.
Latest:
Pearls & Perspectives: Innovation in male fertility care with Larry Lipshultz, MD, at AUA 2025Discover groundbreaking insights in urology as Larry Lipshultz, MD, shares innovative research and strategies for male fertility challenges.
Latest:
Laura Davis, MD, on persistent poverty and early onset prostate cancerLaura E. Davis, MD, discusses the link between early onset prostate cancer and persistent poverty.
Latest:
Expert shares advice for ethical adoption of AI in health care“Responsible application of AI is crucial, especially when the health and well being of people are at stake,” writes industry expert Manny Krakaris.
Latest:
Is now a good time to sell your medical practice to a private equity group?Industry expert provides in-depth advice.
Latest:
Strategies for dealing with difficult patientsIn this article, an expert addresses the most common issues that come up with patients that may make them harder to deal with and solutions that may help a provider.
Latest:
Management of hormone-naïve oligometastatic prostate cancerGrowing evidence supports the existence of an intermediate metastatic disease state.
Latest:
Drug interactions to monitor when prescribing erectile dysfunction medicationsMany of the medications used in the treatment of ED have interactions with other medications, so it is crucial to carefully examine patient profiles to optimize therapy and ensure safety.
Latest:
Expert discusses unique mechanism of action of UTI treatment gepotidacin"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.
Latest:
Enhancing Patient-Centric Management in OAB in 2024 and BeyondPanelists conclude their discussion by reflecting on key learnings and sharing advice for patient-centric management in overactive bladder (OAB) treatment, specifically focusing on effective communication and overlooked aspects of patient care. They offer guidance to other providers on enhancing patient experiences, particularly with procedures like Botox. The episode wraps up with each expert sharing their final thoughts and anticipations for advancements in OAB treatment in 2024, highlighting their commitment to addressing patient needs in this evolving field.
Latest:
U.S. News & World Report Names Michigan Institute of Urology’s Town Center ASC Among 2025 Best Ambulatory Surgery CentersAmbulatory surgery centers were evaluated based entirely on objective, risk-adjusted measures of their patients’ outcomes.
Latest:
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy“The takeaway is that on a population level, on a health care system perspective, it's more cost-effective and safer to do transperineal prostate biopsy,” says Mitchell M. Huang, MD.
Latest:
The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.
